Literature DB >> 19409809

Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy.

Frederick W K Tam1, Bruce L Riser, Karim Meeran, JoAnn Rambow, Charles D Pusey, Andrew H Frankel.   

Abstract

Profibrotic growth factors and inflammatory chemokines have been implicated in the pathogenesis of diabetic nephropathy (DN). However, measurement of urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers has not previously been reported, and neither have two such molecules in urine been examined in a single study of DN. In this prospective observational study, 43 adult diabetic patients were studied, 40 were followed up for 6years. Urinary MCP-1/creatinine ratios were found to be significantly higher in patients with macroalbuminuria (3.3- and 2.1-fold higher (p<0.01) than normoalbuminuric and microalbuminuric patients, respectively). CCN2 exhibited a pattern different from that of urinary MCP-1. Urinary CCN2/creatinine ratios were greatly elevated in both microalbuminuric and macroalbuminuric patients (125- and 74-fold higher than normoalbuminuric patients, respectively, p<0.01 and p<0.05, respectively). Further, urinary CCN2, but not MCP-1, correlated with progression of microalbuminuria (R=0.49, p<0.05). In contrast, MCP-1, but not CCN2, correlated with the rate of eGFR decline for all patients (R=0.61, p<0.0001), reflective of its predictive value in patients with macroalbuminuria, but not for patients with microalbuminuria or normoalbuminuria. In conclusion, increased urinary CCN2 is associated with the early progression of DN, whereas MCP-1 is associated with later stage disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409809     DOI: 10.1016/j.cyto.2009.04.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  43 in total

1.  Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Authors:  Gudeta D Fufaa; E Jennifer Weil; Robert G Nelson; Robert L Hanson; William C Knowler; Brad H Rovin; Haifeng Wu; Jon B Klein; Theodore E Mifflin; Harold I Feldman; Ramachandran S Vasan; Paul L Kimmel; John W Kusek; Michael Mauer
Journal:  Nephrol Dial Transplant       Date:  2015-02-03       Impact factor: 5.992

2.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

Review 3.  Urinary biomarkers for early diabetic nephropathy: beyond albuminuria.

Authors:  So-Young Lee; Mary E Choi
Journal:  Pediatr Nephrol       Date:  2014-07-25       Impact factor: 3.714

Review 4.  Novel urinary biomarkers in early diabetic kidney disease.

Authors:  Atsuko Kamijo-Ikemori; Takeshi Sugaya; Kenjiro Kimura
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

Review 5.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

6.  Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.

Authors:  Jeanie B Tryggestad; Rachana D Shah; Barbara H Braffett; Fida Bacha; Samuel S Gidding; Rose A Gubitosi-Klug; Amy S Shah; Elaine M Urbina; Lorraine E Levitt Katz
Journal:  Pediatr Diabetes       Date:  2020-07-02       Impact factor: 4.866

7.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

8.  Glomerular and tubular damage markers in individuals with progressive albuminuria.

Authors:  Ferdau L Nauta; Lieneke Scheven; Esther Meijer; Wim van Oeveren; Paul E de Jong; Stephan J L Bakker; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

9.  Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial.

Authors:  Cheetin C Lee; Stephen J Sharp; Deborah J Wexler; Amanda I Adler
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

Review 10.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.